Annals of Allergy, Asthma & Immunology

UNC Health Provider Ushers in First FDA-Approved Medication for Eosinophilic Esophagitis

Retrieved on: 
Thursday, December 22, 2022
Research, General Health, Pharmaceutical, Other Education, Continuing, University, Education, Clinical Trials, Science, FDA, Other Science, Health, The New England Journal of Medicine, Eosinophilic esophagitis, Esophagus, Immunology, Clinical trial, Plasma protein binding, A. Lee Dellon, Communication, Stomach, American College, UNC School of Medicine, Polyp (medicine), Dysphagia, Skin, Dupilumab, Enzyme inhibitor, Inflammation, Multimedia, Food, American College of Allergy, Asthma and Immunology, Irritation, Eosinophil, Patient, Asthma, Infection, Physician, Parasitism, Swelling, FDA, EOE, Regeneron Pharmaceuticals, Sinusitis, Degenerative disease, Colon, Endoscopy, Diagnosis, MPH, Dermatitis, Annals of Allergy, Asthma & Immunology, Biopsy, Electric battery, Pharmaceutical industry, Medical imaging, MD, Allergy, Medicine

Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.

Key Points: 
  • Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.
  • View the full release here: https://www.businesswire.com/news/home/20221222005534/en/
    Evan Dellon, MD, MPH, professor of medicine at the UNC School of Medicine and director of the Center for Esophageal Diseases and Swallowing.
  • There is one approved treatment for EoE in several other countries, but it is not available for use in the United States.
  • Dellon believes that initially most doctors will prescribe the therapy for their more severe patients who weren’t responding to prior therapies.

CHOP's Food Allergy Bravery Clinic Helps Kids with Food Allergies Overcome Anxiety

Retrieved on: 
Wednesday, September 28, 2022
Food, DOI, Children's Hospital of Philadelphia, Cognitive behavioral therapy, MSN, Eating, Hospital, Immunology, Asthma, FAB, CHOP, Life, Health, CBT, Annals of Allergy, Asthma & Immunology, Philadelphia, Program, Patient, SCARED, Prussia, Quality of life, Anxiety, Doctor of Philosophy, Caregiver, Allergy, Immunoglobulin E, Parent, Research, Food allergy, Education, Allergist, Anaphylaxis, Health insurance, Child

PHILADELPHIA, Sept. 28, 2022 /PRNewswire/ -- From an early age, children with life-threatening food allergies are taught to proceed with caution: check labels, ask about ingredients, don't eat something at a friend's house if you don't know what is in it. In some cases, however, necessary caution evolves into unnecessary avoidance – not only of foods but also of social situations where food might be served. This sort of disordered eating and avoidance is driven by anxiety, which if left unaddressed can significantly derail a child's quality of life and social development.

Key Points: 
  • The Food Allergy Bravery (FAB) program at CHOP provides cognitive behavioral therapy (CBT) in five to eight sessions to children who have severe anxiety related to their food allergies.
  • "This study shows that our Food Allergy Bravery program is a successful treatment for helping children with food allergy anxiety overcome their fears and improve their day-to-day life."
  • The FAB Clinic was launched in 2018 as a collaborative project to address food allergy anxiety.
  • Today, all patients seen with food allergies at CHOP are screened for anxiety and referred to the FAB Clinic as needed.

Professor Peter M. Elias, an expert on the skin barrier, recently praised NEUROMIDE, which promotes ceramide synthesis and strengthens the skin barrier

Retrieved on: 
Friday, May 20, 2022
Immunology, T helper cell, Organic acid, Keratinocyte, Dermatology, Science, Lipid, Review, Annals of Allergy, Asthma & Immunology, Asthma, Technology, A4, SAN, Life, Cholesterol, Skin, MD, Atopic dermatitis, Medical device, Cosmetics, Personal protective equipment, Allergy

SAN FRANCISCO , May 19, 2022 /PRNewswire/ -- The outermost layer of the skin, the stratum corneum, is a thin film with a thickness of about 0.02 mm. The A4 paper we use for copying is about 0.1 mm, meaning the stratum corneum is 1/5 the thickness of this paper. Nevertheless, the stratum corneum is physically very strong, and it plays a vital role in maintaining life in a terrestrial environment – it prevents the loss of internal substances and moisture to the outside atmosphere, while also preventing the intrusion of external microorganisms or the penetration of contaminants into our bodies.

Key Points: 
  • Dr. Raymond Laboratories, Inc developed and only used in CURECODE skin barrier products.
  • The A4 paper we use for copying is about 0.1 mm, meaning the stratum corneum is 1/5 the thickness of this paper.
  • In atopic dermatitis, skin barrier function is weakened, and the levels of inflammatory cytokines such as Th2, Th17, and IL-33, are increased.
  • The chemical structure of NEUROMIDE imitates compounds that the microbiome naturally produces to improve skin barrier function.

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

Retrieved on: 
Friday, March 4, 2022
Pediatrics, Allergy, Immunology, Johns Hopkins School of Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Journal, Public health, American Academy, Annals, The Journal of Allergy and Clinical Immunology, Pediatric Allergy and Immunology, Johns Hopkins Hospital, Food, Safety, Coronavirus Scientific Advisory Board (Turkey), Johns Hopkins Bloomberg School of Public Health, FDA, American Academy of Allergy, Asthma, and Immunology, Peptide, Johns Hopkins Children's Center, Anaphylaxis, Center, Patent, Book, Food allergy, JAMA, Annals of Allergy, Asthma & Immunology, IND, The New England Journal of Medicine, SAB, Peanut allergy, Asthma, American Board of Commissioners for Foreign Missions, Immune system, Clinician Administered PTSD Scale, Allergen, Pharmaceutical industry, Vaccine, Medical device, EU

PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy.

Key Points: 
  • PVX108 is a next-generation, allergen-specific immunotherapy using peptides that represent critical fragments of peanut proteins to precisely target the T cells driving peanut allergy.
  • The presence of whole peanut allergens in those extracts exposes patients to significant risks of anaphylaxis (Chu et al.
  • The IND will allow Aravax to progress the Phase 2 clinical trial program into the U.S. and expand its global operations.
  • The lead product, PVX108, is being developed for the treatment of peanut allergy.

Green Park Collaborative and Allergy & Asthma Network Publish a Core Outcome Set for Clinical Trials in Moderate to Severe Asthma

Retrieved on: 
Tuesday, April 6, 2021
Articles, Medical specialties, Medicine, Clinical data management, Clinical research, Core outcome set, Multistakeholder governance, Annals of Allergy, Asthma & Immunology, Allergy, Stakeholder

The report, published in the Annals of Allergy, Asthma and Immunology, describes the multi-stakeholder consensus process used to prioritize nearly 100 outcomes down to a final set of five core outcomes.

Key Points: 
  • The report, published in the Annals of Allergy, Asthma and Immunology, describes the multi-stakeholder consensus process used to prioritize nearly 100 outcomes down to a final set of five core outcomes.
  • Participants represented many perspectives, including patients, clinicians, researchers, payers, health technology assessors, regulators, and drug development companies.
  • "The coreASTHMA core outcome set is a triumph.
  • Even in a condition like asthma, where the most important outcomes for clinical research might seem self-evident, valuable insights on outcome selection were gained through multistakeholder engagement.